Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458536 · ClinicalTrials.gov registry record · Phase 1
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00458536 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 38 participants.
The verdict
NCT00458536, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The main purpose of this study is to test the safety of the dendritic cell/tumor fusion study vaccine in combination with a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF). Another purpose is to determine the type and severity of any side effects associated with this study vaccine. GM-CSF is similar to a substance in the body that stimulates the production of white blood cells. To create the study vaccine, cells will be removed from the participants tumor and fused with dendritic cells which are obtained from the participants blood. Dendritic cells are responsible for immune responses to "foreign" substances that enter the body. Animal studies have shown that these fused cells can stimulate powerful anti-tumor responses.
Interventions
- BIOLOGICAL Dendritic Cell Tumor Fusion Vaccine
- DRUG Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2004-10 |
| Est. Completion | 2023-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458536
The ClinicalTrials.gov registry entry for NCT00458536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dendritic Cell Tumor Fusion Vaccine is the first listed.
NCT00458536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458536 about?
NCT00458536 is a clinical study titled "Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF". The main purpose of this study is to test the safety of the dendritic cell/tumor fusion study vaccine in combination with a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF). Another purpose is to determine the type and severity of any side effects associated wit...
What is the current status of trial NCT00458536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2004-10. Estimated completion is 2023-07.
What interventions are being tested in trial NCT00458536?
The interventions under investigation include: Dendritic Cell Tumor Fusion Vaccine (BIOLOGICAL), Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) (DRUG).
Who is sponsoring clinical trial NCT00458536?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.